A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections

Table 3

Cure in cUTI, acute pyelonephritis, E. coli eradication, resistance, and adverse event.

Study ID	Wagenlehner et al., 2015	Kaye et al., 2018	Kaye et al., 2019	Seo et al., 2017	Arakawa et al., 2018	Risk ratio	95% CI
Intervention drug	Ceftolozane/tazobactam	Piperacillin/tazobactam	Piperacillin/tazobactam	Piperacillin/tazobactam	Ceftolozane/tazobactam
Clinical cure in cUTI % ()	67.1 (47/70)	92.1 (35/38)	41.57 (35/84)	N/A	72.9 (35/48)	1.21	1.00-1.47
Clinical cure in acute % () pyelonephritis % ()	79 (259/328)	94.1 (95/101)	66 (62/94)	N/A	63.6 (14/22)	0.97	0.89-1.06
Microbiological eradication o E. coli % ()	90.5 (237/262)	84.6 (154/182)	63.2 (84/133)	93.9 (31/33)	83.5 (66/79)	1.15	1.07-1.23
Resistance	2.7 (20/731)	18 (26/142)	3.3 (6/178)	N/A	N/A	0.25	0.14-0.45
Serious adverse events % ()	2.8 (15/533)	4.8 (13/273)	2.6 (6/231)	N/A	11.4 (13/114)	1.15	0.64-2.09
Adverse effects % ()	5.8 (31/533)	4.4 (12/273)	2.2 (5/231)	N/A	58.8 (67/114)	5.11	3.01-8.68